AMGN – Amgen Inc.
Amgen Inc.AMGN
$327.31Name : Amgen Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $176,250,093,568.00
EPSttm : 12.92
Amgen Inc.
$327.31
0.40%$1.30Float Short %
2.63
Margin Of Safety %
5
Put/Call OI Ratio
0.81
EPS Next Q Diff
-0.89
EPS Last/This Y
13.63
EPS This/Next Y
0.69
Price
327.35
Target Price
332.62
Analyst Recom
2.28
Performance Q
9.65
Relative Volume
0.52
Beta
0.45
Ticker: AMGN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-02 | AMGN | 338.39 | 0.95 | 1.24 | 153876 |
| 2025-12-03 | AMGN | 345.42 | 0.95 | 0.97 | 156622 |
| 2025-12-04 | AMGN | 340.15 | 0.92 | 0.23 | 162138 |
| 2025-12-05 | AMGN | 329.41 | 0.89 | 0.46 | 167125 |
| 2025-12-08 | AMGN | 321.31 | 0.91 | 1.36 | 158037 |
| 2025-12-09 | AMGN | 313.83 | 0.87 | 0.52 | 157953 |
| 2025-12-10 | AMGN | 315.73 | 0.86 | 0.52 | 161059 |
| 2025-12-11 | AMGN | 317.35 | 0.86 | 0.56 | 161482 |
| 2025-12-12 | AMGN | 317.71 | 0.84 | 0.40 | 162796 |
| 2025-12-15 | AMGN | 324.28 | 0.86 | 0.29 | 154959 |
| 2025-12-16 | AMGN | 327.18 | 0.88 | 0.49 | 154992 |
| 2025-12-17 | AMGN | 326.38 | 0.87 | 0.73 | 156318 |
| 2025-12-18 | AMGN | 324.38 | 0.88 | 1.02 | 157305 |
| 2025-12-19 | AMGN | 327.25 | 0.88 | 0.46 | 158294 |
| 2025-12-22 | AMGN | 331.46 | 0.80 | 0.76 | 118028 |
| 2025-12-23 | AMGN | 331.32 | 0.80 | 0.37 | 122730 |
| 2025-12-26 | AMGN | 332.89 | 0.79 | 0.45 | 124590 |
| 2025-12-29 | AMGN | 329.64 | 0.80 | 2.33 | 119095 |
| 2025-12-30 | AMGN | 328.58 | 0.81 | 0.79 | 121930 |
| 2025-12-31 | AMGN | 327.33 | 0.81 | 0.51 | 123007 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-02 | AMGN | 338.36 | -10.8 | 5021.1 | 21.24 |
| 2025-12-03 | AMGN | 345.42 | -10.8 | 5256.7 | 21.24 |
| 2025-12-04 | AMGN | 340.15 | -10.8 | 4790.6 | 21.24 |
| 2025-12-05 | AMGN | 329.89 | -10.8 | 4598.4 | 21.24 |
| 2025-12-08 | AMGN | 321.23 | -10.8 | - | 21.24 |
| 2025-12-09 | AMGN | 313.85 | -10.8 | 4695.0 | 21.24 |
| 2025-12-10 | AMGN | 313.85 | -10.8 | 5049.0 | 21.24 |
| 2025-12-11 | AMGN | 317.38 | -10.8 | 5069.0 | 21.24 |
| 2025-12-12 | AMGN | 317.77 | -10.7 | 5003.9 | 21.25 |
| 2025-12-15 | AMGN | 325.31 | -10.7 | 5291.4 | 21.25 |
| 2025-12-16 | AMGN | 325.31 | -10.7 | 4742.6 | 21.25 |
| 2025-12-17 | AMGN | 325.98 | -10.7 | 4661.4 | 21.25 |
| 2025-12-18 | AMGN | 324.42 | -10.7 | 4629.7 | 21.25 |
| 2025-12-19 | AMGN | 327.36 | -10.7 | 5104.1 | 21.25 |
| 2025-12-22 | AMGN | 331.55 | -10.7 | 5146.6 | 21.25 |
| 2025-12-23 | AMGN | 331.36 | -10.7 | 4973.9 | 21.25 |
| 2025-12-26 | AMGN | 332.87 | -10.7 | 4946.3 | 21.25 |
| 2025-12-29 | AMGN | 329.64 | -10.7 | 4861.4 | 21.25 |
| 2025-12-30 | AMGN | 328.70 | -10.7 | 4951.9 | 21.25 |
| 2025-12-31 | AMGN | 327.35 | -10.7 | 4936.1 | 21.25 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-02 | AMGN | -1.32 | -0.56 | 2.49 |
| 2025-12-03 | AMGN | -1.32 | -0.56 | 2.49 |
| 2025-12-04 | AMGN | -1.32 | -0.56 | 2.49 |
| 2025-12-05 | AMGN | -1.32 | -0.56 | 2.49 |
| 2025-12-08 | AMGN | -1.18 | -0.47 | 2.49 |
| 2025-12-09 | AMGN | -1.18 | -0.47 | 2.49 |
| 2025-12-10 | AMGN | -1.18 | -0.47 | 2.66 |
| 2025-12-11 | AMGN | -1.18 | -0.47 | 2.66 |
| 2025-12-12 | AMGN | -1.18 | -0.47 | 2.66 |
| 2025-12-15 | AMGN | -1.18 | -0.48 | 2.66 |
| 2025-12-16 | AMGN | -1.18 | -0.48 | 2.66 |
| 2025-12-17 | AMGN | -1.18 | -0.48 | 2.66 |
| 2025-12-18 | AMGN | -1.18 | -0.48 | 2.66 |
| 2025-12-19 | AMGN | -1.18 | -0.48 | 2.66 |
| 2025-12-22 | AMGN | -1.18 | -0.56 | 2.66 |
| 2025-12-23 | AMGN | -1.18 | -0.56 | 2.66 |
| 2025-12-26 | AMGN | -1.18 | -0.56 | 2.63 |
| 2025-12-29 | AMGN | -1.18 | -0.56 | 2.63 |
| 2025-12-30 | AMGN | -1.18 | -0.56 | 2.63 |
| 2025-12-31 | AMGN | -1.18 | -0.56 | 2.63 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
5.93
Avg. EPS Est. Current Quarter
4.74
Avg. EPS Est. Next Quarter
5.04
Insider Transactions
-1.18
Institutional Transactions
-0.56
Beta
0.45
Average Sales Estimate Current Quarter
9455
Average Sales Estimate Next Quarter
8656
Fair Value
343.43
Quality Score
86
Growth Score
89
Sentiment Score
19
Actual DrawDown %
5.6
Max Drawdown 5-Year %
-24.9
Target Price
332.62
P/E
25.3
Forward P/E
14.88
PEG
3.12
P/S
4.91
P/B
18.32
P/Free Cash Flow
15.27
EPS
12.94
Average EPS Est. Cur. Y
21.25
EPS Next Y. (Est.)
21.93
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
19.52
Relative Volume
0.52
Return on Equity vs Sector %
45.5
Return on Equity vs Industry %
36
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
4936.1
Amgen Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 28000
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
stock quote shares AMGN – Amgen Inc. Stock Price stock today
news today AMGN – Amgen Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AMGN – Amgen Inc. yahoo finance google finance
stock history AMGN – Amgen Inc. invest stock market
stock prices AMGN premarket after hours
ticker AMGN fair value insiders trading